RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function

Area of Science:

• Immunology
• Cancer Biology
• Cell Therapy

Background:

• CAR-T therapy shows success in hematological cancers but faces challenges in solid tumors due to T cell exhaustion.
• The tumor microenvironment in solid tumors contributes to CAR-T cell exhaustion, limiting treatment efficacy.
• RUNX3, a transcription factor, regulates T cell differentiation and tissue residency.

Purpose of the Study:

• To investigate the potential of overexpressing RUNX3 in CAR-T cells to overcome exhaustion and improve efficacy against solid tumors.
• To evaluate the impact of RUNX3 on CAR-T cell phenotype, function, and safety in vitro and in vivo.

Main Methods:

• Overexpression of RUNX3 in CAR-T cells (Runx3-OE CAR-T).
• In vitro assessment of CAR-T cell function, differentiation, and cytokine release upon antigen stimulation.
• In vivo evaluation of anti-tumor efficacy and safety in re-challenge experiments.

Main Results:

• Overexpression of RUNX3 maintained a less differentiated state in CAR-T cells, improving their resistance to exhaustion.
• Runx3-OE CAR-T cells exhibited reduced cytokine release while preserving anti-tumor function in vitro.
• CAR-T cells engineered with RUNX3 demonstrated enhanced safety and maintained anti-tumor efficacy in vivo re-challenge models.

Conclusions:

• RUNX3 overexpression can enhance the phenotype and function of CAR-T cells, potentially improving their safety profile.
• Runx3-OE CAR-T cells represent a promising strategy to improve CAR-T therapy for solid tumors.
• Further clinical investigation of Runx3-OE CAR-T cells may enhance the safety and efficacy of CAR-T therapy.